This phase II clinical trial will test the efficacy of anti-CD3 x anti-Her2/neu bispecific antibody (Her2Bi) armed activated T cells (aATC) immunotherapy following neoadjuvant chemotherapy (chemoT) in women with triple negative (TNBC) operable breast cancer (BrCa) who do not achieve a complete pathologic response (pCR) after neoadjuvant chemoT. TNBC are tumors that are estrogen receptor, progesterone receptor, and Her2/neu (0-2+ by immunohistochemistry) negative. Less than 25% of all patients with TNBC treated with chemoT achieve pCR at surgery. Women with TNBC who do not achieve a pCR after preoperative chemoT, have a much poorer prognosis compared to those who achieve a pCR. New strategies are needed to target these tumors with a very low levels of Her2/neu expression (0-2+). This phase II trial combines anthracycline/taxane-based neoadjuvant chemoT with 4 infusions of aATC to determine whether this combination increases pathological complete responses (pCR) and recurrence free survival. The use of aATC in extremely low Her2/neu expressing tumors is supported by phase I clinical and immunologic data in women with HER2 0-2+ status. ChemoT prior to immunotherapy (IT) will deplete lymphocytes and regulatory cells to optimize T cell expansion and vaccination with in situ tumor lysates resulting from chemoT and IT.
The first aim i s to determine in a phase II clinical trial of women with stage II-III TNBC if a neoadjuvant chemoT followed by IT improves the pCR rate at the time of surgery and to investigate the association between pCR and clinical responses (DFS and OS). IT will consist of 20 x 109 aATC given once per week for 4 weeks.
The second aim i s to determine if aATC will modulate the anti-tumor activity in the blood and tumor and to determine if there is an association between systemic and tumor site immune responses.
The third aim i s to determine if aATC decreases the frequency of putative CD44hi/CD24lo, CD133+, ALDH1 positive breast cancer stem cells (CSC) in the tumor tissue at the time of surgery compared to that found in the tumor biopsy specimen after chemoT and whether such changes in CSC correlate with clinical responses observed in Aim 1. Immune monitoring will occur pre-IT, prior to infusion #3 (midpoint of IT), after IT and prior to surgery, and 1 month after surgery. If this approach induces anti-tumor immunity that clears CSC at the tumor sites and induces long-term anti-tumor immunity, pCRs will increase and recurrence rates will decrease. Such results will be have an extraordinarily high impact for women with TNBC and provide a paradigm shift for use of IT with neoadjuvant chemoT in women with TNBC. Furthermore, this strategy could be applied to a number of solid tumors and hematologic malignancies.
Women with HER2/neu and Hormone Receptors (HR) negative stage II-III ("triple negative" TNBC) operable breast cancer (BrCa) who do not achieve a complete pathologic response (pCR) after neoadjuvant chemotherapy (chemoT) are the focus of this phase II clinical trial. TNBC are tumors that are estrogen receptor, progesterone receptor, and Her2/neu (0-2+ by immunohistochemistry) negative. This phase II trial will test the efficacy of anti-CD3 x anti-Her2/neu bispecific antibody (Her2Bi) armed activated T cells (aATC) following neoadjuvant chemotherapy (chemoT) in women with triple negative (TNBC) operable breast cancer (BrCa) patients. Women with TNBC who do not achieve a pCR after preoperative chemoT have a much poorer prognosis compared to those who do achieve a pCR. Armed ATC can target very low level expression of 0-2+ Her2/neu expressing tumors. New strategies are needed for this group with limited therapeutic options. We propose a phase II clinical trial that combines anthracycline/taxane-based neoadjuvant chemoT followed by 4 infusions of aATC to determine whether this combination improves pathological complete response (pCR) and recurrence free survival. The immune responses and changes in tumor cancer stem cells will be monitored and correlated with the pCR.
|Lum, Lawrence G; Thakur, Archana; Kondadasula, Sri Vidya et al. (2016) Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity. Biol Blood Marrow Transplant 22:869-78|
|Xie, Yuran; Kim, Na Hyung; Nadithe, Venkatareddy et al. (2016) Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release 229:120-9|
|Lum, Lawrence G; Thakur, Archana; Al-Kadhimi, Zaid et al. (2015) Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. Clin Cancer Res 21:2305-14|
|Bhutani, Divaya; Lum, Lawrence G (2015) Activated T cells armed with bispecific antibodies kill tumor targets. Curr Opin Hematol 22:476-83|
|Lum, L G; Thakur, A; Pray, C et al. (2014) Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study. Bone Marrow Transplant 49:73-9|
|Yano, Hiroshi; Thakur, Archana; Tomaszewski, Elyse N et al. (2014) Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med 12:191|
|Lum, Lawrence G; Thakur, Archana; Liu, Qin et al. (2013) CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 19:925-33|
|Thakur, Archana; Vaishampayan, Ulka; Lum, Lawrence G (2013) Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) 5:569-90|
|Zitron, Ian M; Thakur, Archana; Norkina, Oxana et al. (2013) Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer 13:83|
|Yankelevich, Maxim; Kondadasula, Sri Vidya; Thakur, Archana et al. (2012) Anti-CD3â€‰Ã—â€‰anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer 59:1198-205|
Showing the most recent 10 out of 15 publications